Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

search (www.michaeljfox.org).

"We are proud to play a key role in this potentially high-impact project," said Todd Sherer, Ph.D., vice president of research programs at The Michael J. Fox Foundation. "The Foundation continues to believe that trophic factors hold enormous potential to become transformative therapeutics for people with Parkinson's."

The first Phase 2 clinical trial of CERE-120, completed in November 2008, did not meet its pre-designated primary endpoint (Unified Parkinson's Disease Rating Scale- Motor Off at 12 months) although a clinically modest benefit was seen in improving motor performance and quality of life in Parkinson's disease patients, based on statistically significant differences in several secondary endpoints. Even greater improvement was seen following an analysis of all patients who were assessed under blinded conditions at 15 to 18 months post-treatment, including on the primary measure (UPDRS motor off at 18 months, p=0.025). Importantly, new scientific insight regarding degenerating dopamine neurons in the brains of advanced Parkinson's disease patients was gained from CERE-120-treated patients who died of unrelated causes, combined with the clinical results, led to important changes in CERE-120 dosing intended to significantly enhance its bioactivity and response to treatment. This revised dosing paradigm now targets both the terminals (or nerve endings) of the degenerating neurons in a site in the brain called the putamen, as well as the cell bodies of these neurons, located in another brain region called the substantia nigra.

"We are pleased to initiate a new controlled Phase 2b study that is statistically powered to demonstrate the efficacy of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We continue to strongly believe that CERE-120 has the potential to improve the symptoms of Parkinson's disease while also delaying
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , September 4, 2015 ... announces that Hutchison MediPharma Limited ("HMP"), its drug ... the second proof-of-concept ("POC") trial of fruquintinib in ... ("NSCLC") in China .  The ... in meeting the primary efficacy endpoint of progression ...
(Date:9/3/2015)... , Sept. 3, 2015 ... of New Drugs, Industry Changes and Emerging Opportunities ... human ovaries? Visiongain,s new study forecasts those pharmaceutical ... in that industry. You also explore trends, results, ... Our report gives revenue predictions to 2025 at ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... – Your New Guide to that Market, its R&D and ... want to assess the future of cancer-treating medicines? Visiongain,s new ... helping you stay ahead. There you discover financial data, R&D ... In our analysis you see forecasted sales ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine ... Mass., March 4 Decision Resources, one of the ... and healthcare issues, finds that second-line patient share of ... to 35.2 percent since last year,s report. Most of ...
... in Small, Ambulatory Physician PracticesSCHAUMBURG, Ill., March 3 ... Information Technology (CCHIT(R)), the federally recognized body for ... announced it will develop dermatology-specific functionality criteria beginning ... a response to an application from the American ...
Cached Medicine Technology:Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 3Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2
(Date:9/5/2015)... ... September 05, 2015 , ... Watching a cyber nightmare come to life in the privacy ... could do nothing more than sit back helplessly as a hacker took control over their ... And while it may have made the whole situation that much more jarring to the ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article ... color when subjected to an impact force that is great enough to cause a ... or other sporting equipment so that coaches or officials would instantly see if a ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Mile High Connects ... in which a lack of funding for sidewalks, bike paths, and other vital supports ... while the Denver region spends billions of dollars to expand public transit, there’s very ...
(Date:9/4/2015)... Bogart, GA (PRWEB) , ... September 04, 2015 ... ... serving Bogart and the surrounding communities, is launching a charity effort to provide ... , Commonly referred to as an enlarged heart, restrictive cardiomyopathy often leads to ...
(Date:9/4/2015)... ... 04, 2015 , ... Scalability Experts (SE) announced that it ... this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” for ...
Breaking Medicine News(10 mins):Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 2Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 3Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 4Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Missed Connections in Metro Denver Transit 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4
... brain scans of high school football and hockey players showed ... concussion after taking routine hits to the head during ... Rochester Medical Center study. , The research, reported online ... involving a small sample of athletes, but nonetheless raises powerful ...
... Chris Seaton, formerly a captain in the Royal Army ... Science at The University of Manchester, created the easy-to-use ... burns caused to fellow soldiers. Chris, who ... and Professor Paul McArthur, plastic surgeons at St Helens ...
... Granada researchers have proven that infants born to women living ... at birth than those born to mothers living in rural ... xenoestrogens, a type of environmental pollutants that act like hormones. ... a correlation between estrogenic burden in pregnant women,s placenta and ...
... number 7 billion is less likely to die from infectious ... contract diabetes or other non-communicable diseases (NCDs), as they are ... November is official World Diabetes Day. In a world of ... more relevant than ever, according to external lecturer Siri Tellier ...
... carotid artery stenting (CAS) following prior same-side carotid artery ... of in-hospital death, stroke and heart attack compared to ... study received "Best of Session" recognition and will be ... Association annual meeting on November 14 at 9:30 AM ...
... The survival and neuroprotective benefits of therapeutic hypothermia ... with those patients without cardiomyopathy, according to a ... at the American Heart Association (AHA) scientific sessions ... use of therapeutic hypothermia in patients with the ...
Cached Medicine News:Health News:Routine head hits in school sports may cause brain injury 2Health News:Routine head hits in school sports may cause brain injury 3Health News:Burns app could save lives at the touch of a button 2Health News:Prenatal exposure to environmental pollutants determines weight and size at birth 2Health News:Risk of contracting diabetes to increase in world of 7 billion people 2Health News:Risk of contracting diabetes to increase in world of 7 billion people 3Health News:Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure 2Health News:Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy 2
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
Medicine Products: